Astrana Health, Inc. ASTH
- Market cap
- $1.7B
- P/E
- 43.6×
Follow ASTH
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.41 | 5.65 | 13.01 | 13.02 | 9.27 | 18.26 | 26.89 | 27.55 | 31.34 | 20.12 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 9.00 | 25.00 | 30.00 | 23.26 | 19.68 | 133.23 | 74.01 | 40.81 | 63.20 | 39.97 |
High Price
|
|||
| 150 | 493 | 492 | 555 | 630 | 1,133 | 1,362 | 1,800 | 1,900 | 3,000 |
Employees
|
|||
| 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
Revenue/Emp
|
|||
| 306 | 356 | 520 | 561 | 687 | 774 | 1,144 | 1,387 | 2,035 | 3,182 |
Revenue
|
|||
| 16.72% | 23.26% | 30.54% | 16.56% | 21.53% | 22.97% | 17.43% | 15.50% | 13.34% | 10.73% |
Gross Margin
|
|||
| 19 | 50 | 83 | 26 | 178 | 78 | 87 | 90 | 81 | 40 |
EBT
|
|||
| 6.16% | 13.95% | 15.89% | 4.61% | 25.97% | 10.05% | 7.57% | 6.48% | 3.97% | 1.24% |
EBT Margin
|
|||
| 10 | 46 | 60 | 18 | 122 | 46 | 46 | 58 | 50 | 24 |
Net Income
|
|||
| 18 | 22 | 23 | 21 | 20 | 19 | 18 | 19 | 30 | 50 |
Depreciation
|
|||
| 12.40 | 13.96 | 15.81 | 16.15 | 18.81 | 17.66 | 25.44 | 29.79 | 42.75 | 64.83 |
Revenue/Sh
|
|||
| 0.41 | 0.90 | 0.33 | 0.41 | 1.04 | 1.69 | 1.09 | 1.30 | 0.91 | 0.46 |
Earnings/Sh
|
|||
| 0.89 | 2.03 | 0.78 | 0.39 | 1.26 | 1.60 | 1.83 | 1.47 | 1.10 | 2.34 |
Cash Flow/Sh
|
|||
| (0.13) | (0.08) | (0.04) | (0.03) | (0.03) | (0.44) | (0.51) | (0.61) | (0.17) | (0.21) |
Capex/Sh
|
|||
| 0.75 | 1.95 | 0.74 | 0.36 | 1.23 | 1.17 | 1.32 | 0.85 | 0.93 | 2.13 |
Free CF/Sh
|
|||
| 3.55 | 6.43 | 5.52 | 5.54 | 9.06 | 10.36 | 12.10 | 13.25 | 15.06 | 16.16 |
Book Value/Sh
|
|||
| 25 | 26 | 33 | 35 | 37 | 44 | 45 | 47 | 48 | 49 |
Shares
|
|||
| 0.00 | 13.37 | 60.15 | 46.03 | 17.40 | 43.74 | 25.93 | 29.38 | 35.03 | 53.93 |
PE Ratio
|
|||
| 0.00 | 1.59 | 1.26 | 1.14 | 0.97 | 4.16 | 1.11 | 1.30 | 0.74 | 0.38 |
PS Ratio
|
|||
| 0.00 | 3.73 | 3.60 | 3.32 | 2.02 | 7.09 | 2.33 | 2.93 | 2.09 | 1.53 |
PB Ratio
|
|||
| 0.00 | 1.30 | 1.07 | 1.18 | 0.94 | 4.03 | 1.03 | 1.29 | 0.81 | 0.57 |
EV/Sales
|
|||
| 0.00 | 10.03 | 22.96 | 52.35 | 14.38 | 61.02 | 19.98 | 45.05 | 37.29 | 17.48 |
EV/FCF
|
|||
| 22 | 52 | 25 | 14 | 46 | 70 | 82 | 68 | 52 | 115 |
Op' Cash Flow
|
|||
| (3) | (2) | (1) | (1) | (1) | (19) | (23) | (29) | (8) | (10) |
Capex
|
|||
| 19 | 50 | 24 | 13 | 45 | 51 | 59 | 40 | 44 | 104 |
FCF
|
|||
| 31 | 35 | 101 | 224 | 224 | 290 | 280 | 243 | 273 | 248 |
Working Cap'
|
|||
| 0 | 6 | 14 | 242 | 241 | 185 | 205 | 279 | 435 | 1,039 |
Total Debt
|
|||
| (57) | (113) | (94) | 22 | (20) | (102) | (88) | (17) | 146 | 609 |
Net Debt
|
|||
| 88 | 164 | 182 | 192 | 331 | 454 | 544 | 617 | 717 | 793 |
Sh' Equity
|
|||
| 6.20% | 10.09% | 2.16% | 2.27% | 4.87% | 8.18% | 4.93% | 6.39% | 3.77% | 1.26% |
ROA
|
|||
| 23.76% | 42.70% | 63.47% | 9.44% | 16.17% | 17.42% | 14.29% | 8.82% | 6.47% | 3.50% |
ROIC
|
|||
| 26.89% | 33.62% | 6.27% | 7.55% | 14.41% | 17.56% | 9.05% | 10.46% | 6.47% | 2.98% |
ROE
|
|||
Astrana Health, Inc. peers in Medical Care Facilities
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| SNDA Sonida Senior Living, Inc. | $1.8B | 0.0× | Compare |
| CMPS COMPASS Pathways PLC Sponsored ADR | $1.9B | 0.0× | Compare |
| SGRY Surgery Partners, Inc. | $1.9B | 0.0× | Compare |
| ARDT Ardent Health, Inc. | $1.5B | 19.2× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| HCSG Healthcare Services Group, Inc. | $1.4B | 12.2× | Compare |
| MD Pediatrix Medical Group, Inc. | $2.1B | 12.6× | Compare |
| NUTX Nutex Health Inc. | $1.4B | 8.4× | Compare |
| PNTG The Pennant Group, Inc. | $1.4B | 43.4× | Compare |
Astrana Health, Inc. (ASTH) key facts
- Astrana Health, Inc. (ASTH) is a Medical Care Facilities company in the Healthcare sector, listed on Nasdaq.
- Astrana Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 56.4% from fiscal 2024.
- As of September 25, 2026, ASTH traded at $36.37, a market capitalization of $1.7 billion.
- Return on equity was 2.98% and debt-to-equity 1.11.
Astrana Health, Inc. (ASTH) Latest News
23 Sep
Astrana Health shares fell 5.5% after disclosing a material cybersecurity incident at its subsidiary Astrana Health Management. The breach adds to pressure from a securities-law investigation into the company's aggressive acquisition strategy, a $545 million related-party loan, and exposure to 2027 Medicare regulatory changes. The stock has been volatile, up 31.7% year-to-date but about 33% below its 52-week high, illustrating a premium multiple investors are weighing against operational risks. The market reaction underscores sensitivity to disruptions in a physician enablement platform business, amid concerns about governance, related-party transactions, and the potential impact of upcoming Medicare policy shifts on margins. A prior move cited bipartisan reform efforts around prior authorization that could affect payment dynamics for managed care, further complicating the stock's near-term trajectory. Material cybersecurity breach, ongoing securities-law investigation, and related-party loan create governance, compliance, and financial risks that could materially affect future performance and investor sentiment.
15 Aug
Astrana Health's Q2 earnings call drew analyst questions on financial performance, growth initiatives, operational efficiency, and competitive positioning in healthcare services. Earnings call questions can shape short-term investor views on Astrana Health's strategy and results without major structural shifts.
13 Aug
Astrana Health (ASTH) held its Q2 2026 earnings call to review quarterly financial results and company outlook. Quarterly earnings updates typically shift short-term investor sentiment without redefining long-term strategy.
9 Aug
Astrana Health's Q2 results highlight AI-driven operating leverage and strategic expansion shaping its outlook. AI initiatives and expansion plans are positioned to drive operational efficiency and growth.
7 Aug
Astrana Health Inc posted record EPS for Q2 2026 and raised full-year guidance. Record EPS and raised guidance indicate strong results likely to lift stock price and future outlook.
6 Aug
Astrana Health, Inc. released second quarter 2026 financial results. Quarterly earnings directly shape investor views and stock valuation.
Astrana Health, Inc. (ASTH) reported Q2 earnings exceeding analyst estimates. Q2 earnings beat provides moderate positive signal for financial performance and short-term market reaction.
Astrana Health reported Q2 financial results during its earnings call, detailing revenue, profitability metrics, operational updates, and forward guidance. Q2 earnings call discloses performance metrics and outlook that moderately influence near-term stock sentiment and valuation.
Astrana Health exceeded Q2 CY2026 Non-GAAP EPS estimates, driving a 5.1% stock increase. Quarterly earnings beat lifts near-term sentiment without shifting long-term fundamentals.
13 Jul
Astrana Health ACOs generated $120.4 million in gross shared savings for the 2024 performance year. Large ACO savings confirm strong value-based care results that support revenue growth and positive market positioning.
21 May
Astrana Health posted Q1 results and launched an AI platform initiative, prompting questions over whether these moves will reshape its investment outlook and market position. Q1 results paired with an AI platform launch constitute major strategic steps expected to materially alter company trajectory and investor sentiment.
17 May
Astrana Health’s Q1 earnings call included five analyst questions on financial results, growth strategies, operational challenges and future outlook. Analyst questions from the earnings call supply operational details and strategic insights that moderately influence investor sentiment and short-term stock movement.
14 May
Baird raises price target on Astrana Health (ASTH) following strong Q1 results. Analyst price target increase post-Q1 results boosts market sentiment and short-term trading interest without fundamentally altering long-term trajectory.
12 May
Astrana Health reports Prospect deal ahead of schedule with Q1 trends beating expectations. Prospect deal acceleration and superior Q1 performance signal major strategic and operational advancements boosting Astrana Health's trajectory.
Astrana Health (ASTH) delivered strong Q1 results powered by its AI-enabled platform, full-risk model expansion, and operating leverage improvements. AI platform adoption, full-risk expansion, and operating leverage gains represent major strategic shifts boosting ASTH's growth trajectory and profitability.
11 May
Physician Association of California and Astrana Health, Inc. launched a collaboration to strengthen independent primary care practices across California through shared resources, advocacy, and innovative care models. Strategic collaboration with Physician Association of California positions Astrana Health to expand influence in independent primary care and capture larger market share in a key state.
8 May
Astrana Health (ASTH) Q1 2026 earnings call transcript details first-quarter financial results, management commentary, and forward guidance. Q1 earnings transcript discloses financial performance and strategic outlook, significantly influencing stock trajectory and investor sentiment.
Astrana Health, Inc. (ASTH) released Q1 2026 earnings call summary highlighting quarterly financial performance, operational updates, and future outlook. Quarterly earnings summaries reveal financial results and guidance that significantly shape investor sentiment and stock trajectory.
7 May
Astrana Health's Q1 earnings call highlights financial results, operational updates, strategic initiatives, and forward guidance. Q1 earnings highlights disclose key financial metrics and management outlook that significantly influence ASTH's valuation and trajectory.
Astrana Health, Inc. (ASTH) beat Q1 earnings and revenue estimates. Surpassing Q1 earnings and revenue estimates enhances financial performance and investor sentiment, significantly influencing market trajectory.
Astrana Health (NASDAQ:ASTH) beat Q1 CY2026 sales expectations. Beating sales expectations indicates strong revenue growth, positively influencing financial performance and investor sentiment.
Astrana Health, Inc. (ASTH) reported first quarter 2026 financial results. Quarterly earnings reports significantly affect financial performance metrics and investor sentiment.
5 May
Astrana Health, Inc. (ASTH) achieves rapid market share and revenue growth, prompting a valuation assessment amid strong performance indicators. Rapid market share and revenue growth signals major positive shifts in competitive positioning and investor sentiment for ASTH.
4 May
Investors react positively to Astrana Health (ASTH) surging value-based care revenue and earnings. Surging value-based care revenue and earnings indicate strong financial growth, significantly boosting ASTH's market performance and investor sentiment.
14 Apr
Astrana Health, Inc. (ASTH) named surging stock with competitive advantages; two others ignored. Recognition as surging stock with competitive advantages likely boosts investor sentiment and moderately influences performance.
12 Mar
Astrana Health CEO forecasts 20%-30% growth in 2026 despite regulatory volatility, stated at Barclays Conference. CEO's 20%-30% growth projection for 2026 despite regulatory challenges provides significant positive guidance on future performance and investor sentiment.
3 Mar
Astrana Health, Inc. (ASTH) pursues profit turnaround and share buybacks while delaying its 10-K filing. Profit turnaround, buybacks, and 10-K delay signal major strategic financial moves with potential to reshape investor sentiment and performance trajectory.
2 Mar
Astrana Health Inc (ASTH) reported record revenue and strategic growth in Q4 2025 earnings call highlights. Record revenue and strategic growth represent major positive developments likely to boost ASTH's financial trajectory and investor sentiment.
Astrana Health, Inc. (ASTH) Q4 2025 earnings call summary covers financial results, operational updates, and forward guidance. Q4 2025 earnings summary details financial performance and strategic outlook likely to influence ASTH stock trajectory and investor sentiment.
Astrana Health (ASTH) Q4 earnings call highlights financial results, revenue growth, profitability metrics, and forward guidance amid healthcare sector dynamics. Q4 earnings highlights detail financial performance and strategic outlook, driving significant shifts in investor sentiment and market valuation.